Sign inJoin waitlistJoin the waitlist

PH

Paul Haluska

Medical Oncology

Credentials: · ·

History

Medical Oncology
Internal Medicine

Research

Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells
Cancer Research · 2009 · 328 citations
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort…
The Lancet Oncology · 2010 · Last of 15 authors · 275 citations
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer
Cancer Research · 2010 · 254 citations

John Weroha
19 papers · 7 as a resident
Charles Erlichman
12 papers
Scott Kaufmann
11 papers
Andrea Hendrickson
7 papers · 6 as a resident
Alex Adjei
6 papers
Donald Northfelt
6 papers
LH
Lynn Hartmann
6 papers
Gary Keeney
5 papers
Hope Rugo
5 papers
Rita Nanda
5 papers
Angela DeMichele
4 papers
Beth Karlan
4 papers

Grants

Mayo Clinic Ovarian Cancer SPORE
National Cancer Institute · P50
Project lead · $745.6K · Mayo Clinic Rochester
2009–2021
NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis
National Cancer Institute · UM1
Contact PI · $560K · Mayo Clinic Rochester
2014–2019
(PQD5) Avatar-Directed Treatment for Ovarian Cancer
National Cancer Institute · R01
Contact PI · $621.6K · Mayo Clinic Rochester
2014–2018
Mayo Clinic Breast Cancer SPORE
National Cancer Institute · P50
Project lead · $363K · Mayo Clinic Rochester
2005–2016

Clinical trials

Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2007–2012
Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin
Study chair · Completed · Phase 2
Mayo Clinic
2007–2012